MicroRNAs Dependent G‐ELNs Based Intervention Improves Glucose and Fatty Acid Metabolism While Protecting Pancreatic β‐Cells in Type 2 Diabetic Mice
Small · 2025-01 · 21 (4)
DOI: 10.1002/smll.202409501 ↗Kurz gefasst
Fachartikel in der Zeitschrift Small, online erschienen am 08.12.2024. Verfasst von Geetika Bajaj und 7 weiteren Autor:innen. Beteiligte Einrichtung: National Agri-Food Biotechnology Institute (NABI), Sector-81, S.A.S Nagar, Mohali, Punjab, 140306, India. Hauptthemen laut MEDLINE: MicroRNAs, Diabetes Mellitus, Type 2, Insulin-Secreting Cells, Glucose. Die Arbeit wurde bisher 26-mal zitiert (Crossref) und nennt 92 Literaturangaben. Gefördert von: Council of Scientific and Industrial Research, National Agri-Food Biotechnology Institute, Mohali, Department of Biotechnology, Ministry of Science and Technology, India.
Abstract (Originalsprache)
Metabolic disorders such as Type 2 diabetes mellitus (T2DM) imposes a significant global health burden. Plant‐derived exosome like nanoparticles (P‐ELNs) have emerged as a promising therapeutic alternate for various diseases. Present data demonstrates that treatment with Ginger‐derived exosome like nanoparticles (G‐ELNs) enhance insulin dependent glucose uptake, downregulate gluconeogenesis and oxidative stress in insulin resistant HepG2 cells. Furthermore, oral administration of G‐ELNs in T2DM mice decreases fasting blood glucose levels and improves glucose tolerance as effectively as metformin. These improvements are attributed to the enhanced phosphorylation of Protein kinase B (Akt‐2), the phosphatidylinositol 3‐kinase at serine 474 which consequently leads to increase in hepatic insulin sensitivity, improvement in glucose homeostasis and decrease in ectopic fat deposition. Oral administration of G‐ELNs also exerts protective effect on Streptozotocin (STZ)‐induced pancreatic β‐cells damage, contributing to systemic amelioration of T2DM. Further, as per computational tools, miRNAs present in G‐ELNs modulate the phosphatidylinositol 3‐kinase (PI3K)/Akt‐2 pathway and exhibit strong interactions with various target mRNAs responsible for hepatic gluconeogenesis, ectopic fat deposition and oxidative stress. Furthermore, synthetic mimic of G‐ELNs miRNA effectively downregulates its target mRNA in insulin resistant HepG2 cells. Overall, the results indicate that the miRNAs present in G‐ELNs target hepatic metabolism thus, exerting therapeutic effects in T2DM.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- National Agri-Food Biotechnology Institute (NABI), Sector-81, S.A.S Nagar, Mohali, Punjab, 140306, India.
- Department of Biotechnology, Panjab University, Sector 25, Chandigarh, 160014, India.
- Regional Centre for Biotechnology, Faridabad, Haryana, 121001, India.
- National Institute for Implementation Research on Non-Communicable Diseases, Jodhpur, 342005, India.
ORCID-Profile: Nitin Kumar Singhal
Förderung
- Council of Scientific and Industrial Research
- National Agri-Food Biotechnology Institute, Mohali
- Department of Biotechnology, Ministry of Science and Technology, India
Zitieren
APA
Bajaj, G., Choudhary, D., Singh, V., Priyadarshi, N., Garg, P., Mantri, S. S., Rishi, V., & Singhal, N. K. (2025). MicroRNAs Dependent G‐ELNs Based Intervention Improves Glucose and Fatty Acid Metabolism While Protecting Pancreatic β‐Cells in Type 2 Diabetic Mice. Small, 21(4). https://doi.org/10.1002/smll.202409501
Vancouver
Bajaj G, Choudhary D, Singh V, Priyadarshi N, Garg P, Mantri SS, et al. MicroRNAs Dependent G‐ELNs Based Intervention Improves Glucose and Fatty Acid Metabolism While Protecting Pancreatic β‐Cells in Type 2 Diabetic Mice. Small. 2025;21(4). doi:10.1002/smll.202409501
BibTeX
@article{Bajaj2025,
author = {Bajaj, Geetika and Choudhary, Diksha and Singh, Vishal and Priyadarshi, Nitesh and Garg, Priyanka and Mantri, Shrikant Subhash and Rishi, Vikas and Singhal, Nitin Kumar},
title = {MicroRNAs Dependent G‐ELNs Based Intervention Improves Glucose and Fatty Acid Metabolism While Protecting Pancreatic β‐Cells in Type 2 Diabetic Mice},
journal = {Small},
year = {2025},
volume = {21},
number = {4},
doi = {10.1002/smll.202409501}
}
EUVIMED